Last reviewed · How we verify
GSK716155 subcutaneous injections
At a glance
| Generic name | GSK716155 subcutaneous injections |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus (PHASE3)
- Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers (PHASE1)
- Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo. (PHASE1)
- An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide . (PHASE1)
- A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. (PHASE3)
- Dose Ranging Study of Albiglutide in Japanese Subjects (PHASE2)
- Pharmacokinetics/Pharmacodynamics of Albiglutide (PHASE2)
- Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK716155 subcutaneous injections CI brief — competitive landscape report
- GSK716155 subcutaneous injections updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI